JP2007051136A - Use of d-psicose for inhibiting d-fructose concentration rise in blood - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To enable the prevention in the symptom aggravation of obesity, diabetes and metabolic syndrome, the prevention in crisis, and the improvement in symptoms. <P>SOLUTION: This composition for inhibiting D-fructose concentration rise, preferably simultaneously D-glucose concentration rise, in blood, when a carbohydrate and/or a saccharide having or containing the D-fructose as a part of the structure is taken, is characterized by containing D-psicose and/or its derivative as an active ingredient. The composition, wherein the D-psicose is a mixture of D-psicose with D-fructose. The composition is a form selected from a sweetener, a seasoning, a food additive, a food material, a food or a drink, a health drink or a health food, a medicine, or a feed. A method for using D-psicose to inhibit D-fructose concentration rise, preferably simultaneously to inhibit D-glucose concentration rise, in blood, is characterized by giving D-psicose, when a carbohydrate and/or a saccharide having or containing D-fructose as a part of the structure is taken. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to the use of D-psicose to suppress the increase in blood D-fructose concentration.

  Rare sugars refer to monosaccharides that exist in nature but whose abundance is extremely small. Rare sugars are divided into aldoses, ketoses and alcohols by chemical structure. Examples of aldoses include D-allose, examples of ketoses include D-psicose, and examples of alcohols include allitol. However, since most of these rare sugars have been difficult to obtain because they cannot be mass-produced, little research has been done on their physiological and pharmacological activities. Recently, a large-scale production method using enzymes was developed by Iimori et al., Faculty of Agriculture, Kagawa University, and some rare sugars such as D-psicose, D-allose, and allitol have been produced, and research on their biological activities has progressed. It is out.

  From previous research results, it has been clarified that rare sugars have sugars that have an action on sugar metabolism or lipid metabolism. For example, for D-psicose, in vitro experiments, suppression of D-glucose transport in the isolated intestinal tract (Non-patent Document 1), promotion of insulin secretion from rat pancreatic β-cell line (Patent Document 1), vascular endothelial cell line MCP-1 secretion suppression from the human body (Patent Document 1), and body fat accumulation reduction action (Non-Patent Document 2), and in vivo energy (Non-Patent Document 3) , Each has been revealed.

However, many of the effects revealed in previous studies have been seen in in vitro experiments. Moreover, although the effect | action with respect to the pharmacokinetics of D-glucose is known, it is not yet known about the effect | action with respect to the pharmacokinetics of D-fructose.
1999 Science and Technology Comprehensive Research Commission Regional Lead Research Research Results Report “Studies on the Mechanism of Action of Rare Sugars as Pharmaceuticals” Kagawa Medical University, Masaaki Tokuda, Yoshishi Konishi, Atsushi Maeda, 2000 1999 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Tatsuhiro Matsuo, Mineo Hashiguchi, Heisei 12 years 2000 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Tatsuhiro Matsuo, Mineo Hashiguchi, Heisei 13 years International Publication Number W003 / 097820

  Currently there are about 2 million people with diabetes, about 8.8 million people who are strongly suspected of having diabetes, about 7.4 million people who cannot deny the possibility of diabetes, and 23 million people who are considered obese It has been seen. These people often have not only hyperglycemia and overweight but also hyperlipidemia and hyperuricemia. Recently, hyperglycemia, hyperlipidemia and hyperuricemia have been It forms a “triangle” and is regarded as a “metabolic syndrome” as a risk factor that causes cerebrovascular disorders, particularly among lifestyle-related diseases, and causes death and QOL. Among the “death triangle”, hyperglycemia and hyperlipidemia are deeply related to blood concentrations such as D-glucose and D-fructose.

D-glucose is measured as a blood glucose level, and becomes a problem when hyperglycemia is diabetes or the like. With regard to D-fructose, it is known that obesity, hyperlipidemia, or diabetes develops and worsens due to a high concentration in blood and / or repeated rapid increase in blood concentration ( Kobe J. Med. Sci. 48, 125-136, 2002, Diabetes Care 24, 1882-1887, 2001, Am. J. Nutr. 76,911-911, 2002, Am. J. Clin. Nutr. 79, 537-543 , 2004).
Therefore, it is meaningful to suppress an excessive increase in the blood concentration of D-fructose from the viewpoint of preventing or preventing lifestyle-related diseases such as hyperlipidemia or diabetes. Therefore, the present inventor examined the effect of D-psicose on the increase in blood D-fructose concentration using experimental animals.

  The purpose of the present invention based on the results of the above research is to be able to improve hyperglycemia and / or hyperlipidemia, and to prevent the deterioration of symptoms of obesity, diabetes and / or metabolic syndrome, to prevent the onset and / or to improve the symptoms. The present invention provides a composition, a food, a food material, a food additive, a beverage, a drinking water, a drug, a pharmaceutical raw material, a feed and the like containing D-psicose and / or a derivative thereof suitable for a person and / or an animal.

  In addition, the present invention suppresses an increase in blood D-fructose concentration, which comprises providing D-psicose when ingesting carbohydrates and / or sugars containing or containing D-fructose as part of its structure. The purpose is to provide a method for using D-psicose, which is characterized in that it is used in the above. That is, the present invention provides a method for improving hyperglycemia and / or hyperlipidemia, preventing worsening of obesity, diabetes and / or metabolic syndrome symptoms, preventing onset and / or improving symptoms. Objective.

  In the above study, the effect of D-psicose on blood D-fructose concentration when sucrose or D-fructose was administered to experimental animals was examined. In any case, D-psicose increased blood D-fructose concentration. As a result, the present invention was completed through extensive research based on the findings.

  It has already been clarified that D-psicose has an effect of suppressing an increase in blood sugar. In other substances used for the purpose of blood glucose regulation, the property of suppressing the increase in the blood concentration of both D-glucose and D-fructose, which is related to abnormalities of sugar metabolism or lipid metabolism, is It has not been revealed.

The gist of the present invention is the following compositions (1) to (5) that suppress an increase in blood D-fructose concentration.
(1) A composition containing D-psicose as an active ingredient and suppressing an increase in blood D-fructose concentration when a carbohydrate and / or saccharide containing or containing D-fructose as part of its structure is ingested .
(2) The composition according to (1), wherein the composition is a composition that suppresses an increase in D-glucose concentration simultaneously with an increase in blood D-fructose concentration.
(3) The composition according to (1) or (2), wherein D-psicose is D-psicose and / or a derivative thereof.
(4) The composition of (1), (2) or (3), wherein D-psicose is a mixture of D-psicose and D-fructose.
(5) The composition according to (1) to (4), wherein the composition is in a form selected from the group consisting of sweeteners, seasonings, food additives, food materials, foods and drinks, health foods and drinks, pharmaceuticals and feeds. Any composition.

The gist of the present invention is the following method of using D-psicose (6) to (10).
(6) It is used for suppressing an increase in blood D-fructose concentration, which comprises providing D-psicose when ingesting carbohydrates and / or sugars containing or containing D-fructose as part of its structure. How to use D-psicose
(7) The method for using D-psicose according to (6), which is used for suppressing an increase in blood D-fructose concentration and also used for suppressing an increase in D-glucose concentration.
(8) The method for using D-psicose according to (6) or (7), wherein D-psicose is D-psicose and / or a derivative thereof.
(9) The method for using D-psicose according to (6), (7) or (8), wherein D-psicose is a mixture of D-psicose and D-fructose.
(10) A composition in a form selected from the group consisting of sweeteners, seasonings, food additives, food materials, foods and drinks, health foods and drinks, pharmaceuticals and feeds, wherein D-psicose is an active ingredient. A method of using D-psicose according to any one of (6) to (9).

  According to the present invention, D-psicose and / or its derivative as an active ingredient, D-psicose and / or its derivative, carbohydrate and / or sugar containing D-fructose as part of its structure and / or containing it Of suppressing the increase in blood D-fructose concentration when ingesting, a composition having the effect of simultaneously suppressing the increase in blood D-glucose concentration and the increase in D-fructose concentration, and use of these compositions Of D-psicose and / or its derivatives, which suppress the increase in blood D-fructose concentration when ingesting carbohydrates and / or sugars containing and / or containing D-fructose as part of its structure And a method for simultaneously suppressing an increase in blood D-glucose concentration and an increase in D-fructose concentration it can.

The present invention relates to an increase in blood D-fructose concentration or an increase in blood D-glucose concentration and D-fructose concentration when a carbohydrate and / or saccharide containing and / or containing D-fructose as part of its structure is ingested. Food, health food, food for patient, food material, food material for health, food material for health care, food material for patient, food characterized by suppressing simultaneous increase and containing D-psicose and / or its derivative as an active ingredient Additives, Health Food Additives, Patient Food Additives, Beverages, Health Beverages, Patient Beverages, Drinking Water, Health Drinking Water, Patient Drinking Water, Drugs, Pharmaceutical Raw Materials, Feeds, Livestock and / or Diseases Animal feed can be provided.

  The present invention also relates to an increase in blood D-fructose concentration or an increase in blood D-glucose concentration and D-fructose when a carbohydrate and / or saccharide containing and / or containing D-fructose as part of its structure is ingested. A method for suppressing the simultaneous increase in concentration can be provided.

  The present invention is intended for humans and / or animals, and suppresses a rapid increase in blood D-fructose concentration when a carbohydrate and / or saccharide containing D-fructose as part of and / or containing D-fructose is ingested. It is possible to prevent or treat the development and progression of lifestyle-related diseases such as obesity, diabetes, metabolic syndrome, hyperglycemia, hyperglycemia and / or abnormal carbohydrate metabolism and / or lipids such as metabolic syndrome The present invention relates to a composition, a food, a food material, a food additive, a beverage, drinking water, a drug, a pharmaceutical raw material, and a feed containing D-psicose suitable for humans and / or animals showing metabolic abnormalities. The present invention also relates to a method for suppressing a rapid increase in blood D-fructose concentration when a carbohydrate and / or saccharide containing D-fructose as part of its structure and / or containing it is ingested.

  With regard to D-psicose in recent years, the appearance of epimerase (for example, see JP-A-6-125576) makes it possible to produce it from D-fructose, which is a monosaccharide abundant in nature. However, it has become relatively easy to obtain. It has been found that by using D-fructose as a raw material, the problem of raw material cost is solved, and a hetero-oligosaccharide that can be expected to have a new physiological activity based on D-psicose is obtained. Among monosaccharides, D-psicose is a hexasaccharide having a ketone group as a reducing group. This D-psicose is known to have D-form and L-form as optical isomers. Here, D-psicose is a known substance but rarely exists in nature. Therefore, it is defined as “rare sugar” according to the definition of the International Society of Rare Sugars.

Rare sugars can be defined as monosaccharides (aldoses, ketoses and sugar alcohols) that exist only rarely in nature. Also in the present invention, it is a rare sugar based on the above definition, preferably ketose D-psicose. This definition is ambiguous because it is not defined by the structure or properties of sugar. That is, there is no definition of an amount such as a rare sugar that is a certain amount or less. However, in general, there are six types of aldoses that exist in large quantities in nature: D-glucose, D-galactose, D-mannose, D-ribose, D-xylose, and L-arabinose. Other aldoses are defined as rare sugars. The As ketose, D-fructose exists, and other ketoses can be said to be rare sugars. Other ketoses include D-tagatose, D-sorbose, L-fructose, L-psicose, L-tagatose, and L-sorbose. Sugar alcohols can be produced by reducing monosaccharides, but D-sorbitol is relatively large in nature, but the others are quantitatively small, so these are also rare sugars.
The rare sugar D-psicose used in the present invention has heretofore been difficult to obtain itself, but a method for mass-producing rare sugars from monosaccharides existing in large quantities in nature is being developed. Can be manufactured.

  The derivative of D-psicose used in the present invention will be described. A compound obtained by converting the structure of a molecule from a certain starting compound by a chemical reaction is called a derivative of the starting compound. Derivatives of hexose containing D-psicose include ester, ether, and sugar alcohols (when monosaccharides are reduced, aldehyde groups and ketone groups become alcohol groups and polyhydric alcohols of the same number as carbon atoms) And uronic acid (oxidized monosaccharide alcohol group, D-glucuronic acid, galacturonic acid and mannuronic acid are known in nature), amino sugar (OH group of sugar molecule is replaced with NH2 group) , Glucosamine, chondrosamine, glycoside, etc.) are common, but are not limited thereto.

  Rare sugars are naturally occurring monosaccharides, albeit in trace amounts. D-psicose is not reported to be toxic to humans and is considered to be less toxic to animals. D-psicose is soluble in water and has a refreshing sweetness that is about 60% stronger than sucrose. Its sweetness is refined and refreshing, and there is no bitterness or astringency like saccharin. Rather, it is similar to the sweetness of fructose. D-psicose is in harmony with other tastes of various substances such as acidity, salt to taste, astringency, umami, bitterness, etc., for sweetening and taste improvement of ordinary foods and beverages, quality improvement, etc. Can be advantageously used. This study revealed that D-psicose also suppressed an increase in the blood concentration of D-fructose.

Compositions targeted by the present invention (food, health food, patient food, food material, health food material, patient food material, food additive, health food additive, patient food additive, beverage, Health drink, patient drink, drink water, health drink water, patient drink water, medicine, pharmaceutical raw material, feed, livestock and / or feed for livestock) is edible containing D-psicose and / or its derivatives And / or any medicinal composition.
The composition containing D-psicose as an active ingredient has a form selected from the group consisting of food additives, food materials, food and drink, pharmaceuticals / quasi drugs, and feed for suppressing an increase in blood D-fructose concentration. Is. Utilizing the functionality of the composition, it has become possible to develop healthy foods and drinks, foods containing nutritional foods and drinks for patients, and feeds for domestic animals such as livestock, poultry and fish.
That is, the said food / beverage products are a functional food, a dietary supplement, or a health food / beverage product for suppressing the blood D-fructose density | concentration raise. The feed is a feed for livestock, poultry and pets for suppressing an increase in blood D-fructose concentration. Specifically, the food material of the composition containing the above-mentioned D-psicose as an active ingredient can be used in any form of food form, beverage form or feed form.
In the case of using the above-described functionality of the composition containing D-psicose of the present invention as an active ingredient, the content is not particularly limited, but is appropriately determined depending on the degree of intended function, usage mode, usage amount, etc. It can adjust, for example, is 0.05-100 mass%. The composition for suppressing an increase in blood D-fructose concentration of the present invention can be used for the human body, other foods and drinks, pharmaceuticals, feeds and skin external preparations. It can also be taken orally or applied to the skin. Can be incorporated into oral and parenteral products according to conventional methods and used in various fields such as seasonings, food additives, food ingredients, food and drink, health food and drink, topical skin preparations, pharmaceuticals and feed Can do. For example, when blended in food or drink, food or drink for treating or preventing a disease for which an increase in blood D-fructose concentration should be suppressed can be provided. From the effect of prevention, it can be expected to be used as health food, nutritional food and the like. In addition, it can be used for livestock and / or fish feed and feed. By using it for the human body and other foods and drinks, pharmaceuticals, fertilizers, feeds and external preparations for skin, it is possible to obtain an effect of treating or preventing a disease for which an increase in blood D-fructose concentration should be suppressed.

  In the composition of the present invention, D-psicose and / or a derivative thereof is usually blended so as to be contained at 0.1 to 50% by weight in the composition. Preferably it is 1-50 weight%, More preferably, it is 10-30 weight%. However, when the content is low, the intake of the composition may be increased, and when the content is high, the intake of the composition may be reduced. Therefore, the blending ratio can be generally used in foods and drinks at a blending ratio close to the lower limit, but can be used at a blending ratio close to the upper limit when used in medicines, tablets and capsules. When humans take D-psicose and / or its derivatives, the dosage should be determined by the individual's age, weight, symptoms, etc., but in many cases the effective dose is from 1 to 1 per adult D-psicose It is appropriate to take 50g in divided portions before meals, after meals or with meals. In the case of oral administration, D-psicose and / or its derivatives are preferably administered to adults at a daily dose of 0.3 to 50 g as D-psicose, but may be appropriately increased or decreased depending on age and symptoms. Is possible. The daily dose of the blood glucose elevation inhibitor of the present invention is preferably taken once a day, divided into 2 or 3 times a day at an appropriate interval, or before, after or after meals.

  When the composition of the present invention is used for food, it can be prepared as it is, in a form diluted with oil, a milk form meal, or a form to which a carrier generally used in the food industry is added. Also good. The form of the beverage is a non-alcoholic beverage or an alcoholic beverage. Non-alcoholic beverages include, for example, non-carbonated beverages such as carbonated beverages, fruit juice beverages, and nectar beverages, soft drinks, sports beverages, tea, coffee, cocoa, and other general foods such as medicinal liquors in the form of alcoholic beverages. Can be mentioned. Examples of the form of use of the composition of the present invention as a food material or food additive for the purpose of improving abnormal sugar metabolism and / or abnormal lipid metabolism include powders or granules dissolved in tablets, capsules, beverages, etc. Solid agents, semi-solid bodies such as jelly, liquids such as drinking water, and high-concentration solutions used after dilution. Furthermore, the composition of the present invention can be appropriately added to foods to provide a health food or sick food for the purpose of improving abnormal carbohydrate metabolism and / or abnormal lipid metabolism. As optional components, vitamins, carbohydrates, pigments, fragrances and the like that are usually added to foods can be appropriately blended. The food can be eaten in any form, liquid or solid. It can be eaten as a soft capsule encapsulated by gelatin or the like. The capsule is made of, for example, a gelatin film prepared by adding water to raw material gelatin and dissolving it, and adding a plasticizer (glycerin, D-sorbitol, etc.) thereto.

  The drinking water of the present invention will be described. Glucose metabolism disorders and lipid metabolism disorders often appear from an imbalance between calorie intake and calorie consumption, but treatment is difficult because the causes are deeply rooted in lifestyle habits. For these abnormalities, various therapeutic agents are currently used in Japan, but the occurrence of side effects during long-term administration is a problem. For this reason, lifestyle modification and exercise due to dietary restrictions and the like are regarded as important treatment methods for abnormal carbohydrate and / or lipid metabolism. However, dietary restrictions and exercise are a great stress for people with abnormal carbohydrate and / or lipid metabolism such as obesity and diabetes. In addition, there is a situation where nutritional balance is lost due to an error in dietary restrictions and the physical condition is further deteriorated.

  The drinking water of the present invention is a colorless and transparent, odorless and almost tasteless aqueous solution containing 1 to 5% by weight of D-psicose and / or a derivative thereof. Preferably it is 1.5 to 4 weight%, More preferably, it is 2-3 weight%. If the amount is less than 0.1% by weight, the effect of improving carbohydrate metabolism abnormality and / or lipid metabolism abnormality is not sufficient, and if it exceeds 5% by weight, it is not tasteless. This drinking water is colorless and transparent, does not smell, and has a faint sweetness. Therefore, it can be used as drinking water as it is, and can also be used for cooking rice, cooking, tea, coffee and the like. By using the drinking water of the present invention in this way for making a daily meal or a favorite product, it is possible to improve an abnormality in carbohydrate metabolism and / or an abnormality in lipid metabolism without being particularly conscious. In addition, from the research results on which the present invention is based, it is presumed that the blood D-fructose concentration will not be significantly reduced below the normal value, so that the sugar concentration in the blood can be adjusted more safely. It is considered possible. This is beneficial for improving the quality of life of people suffering from abnormal carbohydrate and / or lipid metabolism such as obesity, diabetes and metabolic syndrome.

  Specific examples of food and drink include the following. Pastry (pudding, jelly, gummy candy, candy, drop, caramel, chewing gum, chocolate, pastry, butter cream, custard cream, cream puff, hot cake, bread, potato chips, french fries, popcorn, biscuits, crackers, pie, sponge Cakes, castella, waffles, cakes, donuts, biscuits, cookies, rice crackers, rice crackers, rice cakes, manju, candy, etc., dried noodle products (macaroni, pasta), egg products (mayonnaise, fresh cream), beverages (functional beverages, Lactic acid beverages, lactic acid bacteria beverages, concentrated dairy beverages, fruit juice beverages, fruit juice beverages, pulp beverages, transparent carbonated beverages, carbonated beverages with fruit juice, fruit colored carbonated beverages), luxury products (green tea, tea, instant coffee, cocoa, canned Coffee Milk), dairy products (ice cream, yogurt, coffee milk, butter, butter sauce, cheese, fermented milk, processed milk), pastes (marmalade, jam, flower paste, peanut paste, fruit paste, fruit syrup) , Livestock meat products (ham, sausage, bacon, dry sausage, beef jerky, lard), seafood products (fish meat ham, fish sausage, salmon, chikuwa, hampen, dried fish, bonito, bonito, boiled, sea urchin Salted fish, plums, dried fish, shellfish, salmon products such as salmon), boiled fish (small fish, shellfish, wild vegetables, salmon, kelp), curry (improvised curry, retort curry, canned curry), seasoning (Miso, powdered miso, soy sauce, powdered soy sauce, moromi, fish sauce, sauce, ketchup, oyster sauce, solid bouillon List of grilled meat sauce, curry roux, stew sauce, soup sauce, soup stock, paste, instant soup, sprinkle, dressing, salad oil), fried products (fried food, fried confectionery, instant ramen), soy milk, margarine, shortening, etc. be able to.

  The said food and drink can be processed and manufactured by mix | blending a composition with the raw material of a general food according to a conventional method. Although the compounding quantity of the composition to the said food-drinks changes with forms of food and is not specifically limited, Usually, 0.1 to 50 weight% is preferable.

  The above food and drink can also be used as functional foods, nutritional supplements or health foods. The form is not particularly limited, and examples of food production include milk proteins with high amino acid balance, soy protein, and proteins such as egg albumin, degradation products thereof, and egg white oligos. In addition to peptides, soybean hydrolysates, and the like, mixtures of amino acids alone can be used according to conventional methods. It can also be used in the form of a soft capsule, a tablet or the like.

  Examples of dietary supplements or functional foods include liquid foods, semi-digested nutritional foods, ingredient nutritional foods, drinks, capsules, and sucrose containing sugars, fats, trace elements, vitamins, emulsifiers, and fragrances. Processing forms such as enteral nutrients can be mentioned. In the above-mentioned various foods, for example, foods and drinks such as sports drinks and nutritional drinks are further supplemented with nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices and fragrances to improve nutritional balance and flavor. , Pigments and the like can also be blended.

  In order to stabilize the composition of the present invention, an antioxidant such as tocopherol, L-ascorbic acid, BHA, rosemary extract and the like can be used in combination according to a conventional method.

The composition of the present invention can be applied to feed for livestock, poultry and pets. For example, it can mix | blend with livestock feeds, such as dry dog food, dry cat food, wet dog food, wet cat food, semi-moist dock food, poultry feed, cattle, and pigs. The feed itself can be prepared according to a conventional method.
These therapeutic agents and preventive agents are non-human animals, for example, domestic mammals such as cattle, horses, pigs and sheep, poultry such as chickens, quails and ostriches, reptiles, birds and pets such as small mammals, It can also be used for farmed fish.

  The chemical | medical agent of this invention is demonstrated. The present inventor conducted an experiment on the effect of D-psicose to suppress an increase in blood D-fructose concentration when a carbohydrate and / or saccharide containing and / or containing D-fructose as part of its structure is ingested. The animals were examined in detail. As a result, it was found that D-psicose has a strong effect of suppressing an increase in blood D-fructose concentration.

  The above-mentioned drugs for improving the abnormalities of carbohydrate metabolism and / or lipid metabolism abnormalities containing D-psicose and / or its derivatives as active ingredients are used alone, as well as general excipients and stabilizers. , Preservatives, binders, disintegrants and other suitable additives, liquids, granules, fine granules, powders, tablets, capsules, pills, ointments, patches, sprays, sprays or An appropriate dosage form such as an injection can be selected and formulated, and can be administered orally, nasally, transdermally or intravenously.

  When clinically applying the composition of the present invention as a drug, D-psicose and / or a derivative thereof as an active ingredient is used as a solid, semi-solid or liquid pharmaceutical carrier such as a diluent, excipient, stabilizer, etc. It is desirable to make it a preparation containing the above additives. The ratio of the active ingredient to the carrier component can vary between 1 and 90% by weight. The dosage form and mode of administration include liquids, granules, fine granules, powders, tablets, capsules, pills, ointments, patches, sprays, sprays, injections, etc. Oral administration may be carried out as it is. When used as a liquid, it may be administered nasally or intravenously in addition to oral administration.

  A pharmaceutical organic or inorganic solid, semi-solid or liquid carrier, solubilizer or diluent suitable for oral, nasal, transdermal or intravenous administration is prepared using the composition of the present invention as a medicament. Can be used for All water, gelatin, lactose, starch, magnesium stearate, talc, animal and vegetable oils, benzyl alcohol, gum, polyalkylene glycol, petroleum resin, coconut oil, lanolin, or other carriers used in medicine are all It can be used as a carrier for a medicament containing the composition of the invention. Further, stabilizers, wetting agents, emulsifiers, and salts for changing the osmotic pressure or maintaining an appropriate pH of the compounding agent can be appropriately used as auxiliary agents.

  Furthermore, the drug containing the composition of the present invention contains other pharmaceutically effective components that can be appropriately administered together with the drug of the present invention in improving abnormal carbohydrate metabolism and / or abnormal lipid metabolism. Also good. In the case of granules, fine granules, capsules, powders, tablets, ointments, patches, sprays or sprays, the composition of the present invention is preferably contained in an amount of 5 to 80% by weight. Alternatively, in the case of an injection, the corresponding amount (ratio) is preferably 1 to 80% by weight.

  In the case of oral administration, the daily dose of D-psicose and / or a derivative thereof is preferably taken as an oral dose of 1-50 g for adults, but may be increased or decreased as appropriate depending on age, symptoms and the like. . The daily dose of the agent of the present invention is preferably administered once a day or divided into two or more times at an appropriate interval, or before, after or with a meal.

  The preparation raw material of the present invention will be described. When producing other drugs or the like for the purpose of improving abnormal sugar metabolism and / or abnormal lipid metabolism as pharmaceuticals, D-psicose and / or derivatives thereof as a raw material for preparation, general excipients, stabilizers, It can also be used for purposes such as preservatives, binders, and disintegrants. Alternatively, for example, when a glucose metabolism disorder and / or lipid metabolism disorder appear secondary, it is necessary to improve the carbohydrate metabolism disorder and / or lipid metabolism disorder in addition to the treatment of the causative disease. In such cases, the composition of the present invention can be used as a raw material for the preparation as described above for the production of a causative disease therapeutic agent. In this case, the amount of D-psicose and / or its derivative used and the ratio with other drugs can be appropriately adjusted depending on the content or nature of these therapeutic agents in the preparation.

[Action]
In rats, oral administration of D-psicose strongly suppressed an increase in blood D-fructose concentration due to oral administration of sucrose or D-fructose.

  The present invention will be described in more detail with reference to examples. However, the present invention is not limited to the examples.

(experimental method)
10 male Wistar rats weighing about 250g per group, sucrose 2g / kg oral administration group (S group), sucrose 2g / kg D-psicose 0.5g / kg mixture administration group (S + P0.5 group) And sucrose 2 g / kg · D-psicose 1 g / kg mixture administration group (S + P1 group). After the animals were fasted for 24 hours, 10 ml / kg of a sugar solution was forcibly administered orally using a stomach tube.
When examining the effect of oral administration of D-psicose on the increase in blood D-fructose concentration by oral administration of D-fructose, 10 male Wistar rats weighing approximately 250 g were used as a group, and 1 g / kg of D-fructose was used. And D-psicose 0.5 or 1 g / kg was orally administered by gavage.
Approximately 200 μL of blood was collected from the plantar vein immediately before administration of the sugar solution and at 15 minutes, 30 minutes, 60 minutes, 120 minutes, and 240 minutes after administration, and the serum was separated. The D-fructose concentration in serum was electrochemically detected and measured using a liquid chromatograph apparatus.
The measured values were expressed as mean values and standard errors, and the significant difference test was performed using Tukey's multiple range test.

(Experimental result)
The rat blood D-fructose concentration after fasting for 24 hours was about 9 mg / dL. In the animals of group S, the blood concentration of D-fructose increased 15 minutes after sucrose administration, and reached 16.4 mg / mL after 30 minutes. Thereafter, the blood concentration at 30 minutes after administration was maximized, and the blood concentration of D-fructose decreased, and returned to the value before sucrose administration 120 minutes after administration.
In the S + P0.5 group and the S + P1 group, there was no increase in blood D-fructose concentration, which was almost completely suppressed. There was no difference in the intensity of suppression of the increase in blood concentration of D-fructose depending on the dose of D-psicose (FIG. 1).

  Even when D-fructose 1 g / kg was orally administered, the blood D-fructose concentration rapidly increased and reached 20.1 mg / dL 30 minutes after administration, showing the maximum value. This blood D-fructose concentration dropped rapidly from 1 hour after administration, and returned to the value almost immediately before administration 2 hours after administration. When D-psicose 0.5 g / kg was orally administered at the same time as D-fructose 1 g / kg, the blood D-fructose concentration was almost the same as that of D-fructose 1 g / kg alone. As shown, the blood D-fructose concentration at 30 minutes and 1 hour after administration became lower, and a significant difference was observed compared to the case of D-fructose 1 g / kg alone. When D-psicose 1 g / kg was orally administered at the same time as D-fructose 1 g / kg, the increase in blood D-fructose concentration was strongly suppressed, and blood D- after 15 and 30 minutes and 1 hour after administration. A significant difference was observed in the fructose concentration compared to the case of D-fructose 1 g / kg alone. The blood D-fructose concentration in the D-psicose administration group continued to decline gradually after 2 hours of administration, and after 4 hours of administration, the blood D-fructose concentration was significant compared to the case of D-fructose 1 g / kg alone. (Figure 2).

(Discussion)
D-glucose is measured as a blood glucose level, and becomes a problem when hyperglycemia is diabetes or the like. As for D-fructose, it is said that when high concentration in blood is sustained, obesity, hyperlipidemia or diabetes develops or deteriorates (Non-patent Document 7, Non-Patent Document 8, Non-patent Document Patent Document 9, Non-Patent Document 10). Therefore, suppressing excessive rise in the blood concentration of D-fructose is significant from the viewpoint of preventing or preventing lifestyle-related diseases such as hyperlipidemia or diabetes. It was revealed that the increase in the blood concentration of D-fructose was also suppressed. This effect appeared more strongly than the effect of suppressing the increase in blood sugar during sucrose administration. This is because D-psicose and D-fructose both belong to ketose, so D-psicose may more strongly suppress the transport of D-fructose in the intestine than the transport of D-glucose belonging to aldose. It suggests.
In other substances used for the purpose of blood glucose regulation, the property of suppressing the increase in the blood concentration of both D-glucose and D-fructose, which is related to abnormalities of sugar metabolism or lipid metabolism, is It has not been revealed.
As described above, D-psicose suppresses an increase in the blood concentration of not only D-glucose but also D-fructose, so that it is caused by abnormalities in glucose metabolism or lipid metabolism such as obesity, hyperlipidemia, diabetes or metabolic syndrome. It provides an extremely useful means for preventing lifestyle-related diseases, improving symptoms and / or preventing deterioration.

According to the present invention, it has been clarified for the first time that D-psicose and / or a derivative thereof exhibits an effect of suppressing an increase in blood D-fructose concentration in experimental animals. This is a result of presuming that D-psicose and / or a derivative thereof exhibits an effect of improving hyperglycemia and / or hyperlipidemia in humans, such as obesity, hyperlipidemia, diabetes or metabolic syndrome. It provides a new means for preventing and coping with lifestyle-related diseases caused by abnormal sugar metabolism or lipid metabolism.

Effect of D-psicose (D-psicose) on blood D-fructose (D-fructose) concentration increase by oral administration of sucrose [In the figure, **; p <0.01 (vs Sucrose 2 g / kg) ), N = 10]. Effect of D-psicose on blood D-fructose concentration increase by oral administration of D-fructose [in the figure, *; p <0.05, **; p <0.01 (vs Fructose 1 g / kg), N = 10 ].

Claims (10)

  A composition comprising D-psicose as an active ingredient and suppressing an increase in blood D-fructose concentration when a carbohydrate and / or saccharide containing or containing D-fructose as part of its structure is ingested.   The composition according to claim 1, wherein the composition is a composition that suppresses an increase in D-glucose concentration simultaneously with an increase in blood D-fructose concentration.   The composition according to claim 1 or 2, wherein the D-psicose is D-psicose and / or a derivative thereof.   4. The composition of claim 1, 2 or 3 wherein D-psicose is a mixture of D-psicose and D-fructose.   The composition according to any one of claims 1 to 4, wherein the composition is in a form selected from the group consisting of sweeteners, seasonings, food additives, food materials, foods and drinks, health foods and drinks, pharmaceuticals and feeds. .   It is used for suppressing increase in blood D-fructose concentration, which comprises providing D-psicose when ingesting carbohydrates and / or sugars containing or containing D-fructose as part of its structure How to use D-psicose.   The method for using D-psicose according to claim 6, wherein the method is used for suppressing an increase in blood D-fructose concentration and simultaneously for suppressing an increase in D-glucose concentration.   The method for using D-psicose according to claim 6 or 7, wherein the D-psicose is D-psicose and / or a derivative thereof.   The method for using D-psicose according to claim 6, 7 or 8, wherein the D-psicose is a mixture of D-psicose and D-fructose. D-psicose is a composition in a form selected from the group consisting of sweeteners, seasonings, food additives, food materials, foods and drinks, health foods and drinks, pharmaceuticals and feeds, containing D-psicose as an active ingredient Item 10. A method of using D-psicose according to any one of Items 6 to 9.